Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Assets (2016 - 2025)

CorMedix's Assets history spans 13 years, with the latest figure at $826.1 million for Q4 2025.

  • For Q4 2025, Assets rose 595.14% year-over-year to $826.1 million; the TTM value through Dec 2025 reached $826.1 million, up 595.14%, while the annual FY2025 figure was $826.1 million, 595.14% up from the prior year.
  • Assets for Q4 2025 was $826.1 million at CorMedix, up from $750.9 million in the prior quarter.
  • Across five years, Assets topped out at $826.1 million in Q4 2025 and bottomed at $57.0 million in Q2 2023.
  • The 5-year median for Assets is $75.4 million (2021), against an average of $161.9 million.
  • The largest annual shift saw Assets dropped 22.94% in 2022 before it skyrocketed 867.78% in 2025.
  • A 5-year view of Assets shows it stood at $68.9 million in 2021, then dropped by 10.02% to $62.0 million in 2022, then surged by 47.38% to $91.4 million in 2023, then grew by 29.99% to $118.8 million in 2024, then surged by 595.14% to $826.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Assets are $826.1 million (Q4 2025), $750.9 million (Q3 2025), and $252.6 million (Q2 2025).